Optimized Costimulatory Domains Boost Tumor Killing in CAR NK Cells

Optimized costimulatory domains boost tumor killing in CAR NK cells

Researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, such as 2B4 and DAP12.

Engineered CAR-NK cells appear more 'attack-ready'

Researchers at the Ribeirao Preto Blood Center and the Center for Cell-Based Therapy (CTC) conducted a study using the NK-92 cell line to test new models of chimeric antigen receptors (CARs) with specific costimulatory domains, such as 2B4 and DAP12. The tests showed that these components helped make the cells "ready to attack," thereby increasing their ability to destroy tumors. The results were published in the journal Frontiers in Immunology.

Innovative Approaches Enhance CAR-NK Therapy Efficacy in Cancer Treatment

A groundbreaking study conducted by researchers at the Ribeirão Preto Blood Center and the Center for Cell-Based Therapy (CTC) at the University of São Paulo has unveiled novel strategies to enhance the efficacy of chimeric antigen receptor-natural killer (CAR-NK) cell therapy against cancer. By employing the NK-92 cell line, this research delves into the profound […]